Table 1. Patients’ characteristics.
| Psoriasis - DMF |
Psoriasis + DMF |
Healthy controls |
P-value1 | |
|---|---|---|---|---|
| N (patients) | 30 | 28 | 32 | |
| Age (mean yrs, SD) | 46.1 (13.9) | 42.7 (14.1) | 42.6 (14.1) | P = 0.54 |
| Gender (% female) | 60.0 | 50.0 | 62.5 | P = 0.52 |
| Smoking (%) | 20.0 | 28.6 | 6.3 | P = 0.07 |
| BMI (mean, SD) | 27.8 (5.3) | 27.2 (4.5) | 25.3 (4.8) | P = 0.11 |
| Caucasian (%) | 80.0 | 82.1 | 81.3 | P = 0.98 |
|
Age at diagnosis (mean yrs, SD) |
30.8 (12.2) | 25.4 (11.8) | NA | P = 0.09 |
|
Disease duration (mean yrs, SD) |
15.7 (11.6) | 17.0 (11.1) | NA | P = 0.67 |
| Psoriasis type n (%) | ||||
| Vulgaris | 25 (83.3) | 25 (89.3) | NA | |
| Guttate | 3 (10.0) | 2 (7.1) | NA | |
| Palmoplantaris | 2 (6.7) | 1 (3.6) | NA | |
| Psoriasis therapy2 | ||||
| Immunosuppressant | 2 | 1 | NA | |
| Local therapy | 15 | 14 | NA | |
| UVB therapy | 2 | 0 | NA | |
| Duration DMF (wks, mean, SD) | NA | 66.8 (94.0) | NA | |
| PASI3 | ||||
| < 10 | 16 (64.0) | 20 (80.0) | NA | |
| >10 en ≤ 20 | 8 (32.0) | 5 (20.0) | NA | |
| >20 | 1 (5.0) | 0 (0) | NA |
DMF, dimethylfumarate; BMI, body mass index; NA, non-applicable
1 P-value calculated by one-way ANOVA for age, BMI; unpaired-t-test for age at diagnosis, disease duration; chi-square test for gender, smoking, ethnicity
2 Patient could have been on concomitant drugs
3 PASI, Psoriasis Area Severity Index for plaque type at time of sample collection (<10 mild, 10–20 moderate, >20 severe). Note that 9 of the 28 patients on DMF are paired with the no-DMF group.